Mario H Cardiel1, Sandra Carrillo2, Marcela Pérez3, Lilia Andrade4, César Pacheco Tena5, Luis H Silveira6, Leonardo Limón7, Sergio Cerpa8, Sergio Gutiérrez Ureña9, Sergio Durán10, Fedra Irazoque Palazuelos4, Sandra Muñoz López4, Sandra Araceli Sicsik Ayala11, Leonor Barile12, María Azucena Ramos Sánchez13, Daniel Grajeda Portes13, Margarita Portela14, Alina Hernández Bedolla14, José Luis García-Figueroa15, Mauricio Montero16, Carlos Abud-Mendoza17, Marco Ulises Martínez Martínez17, David Herrera van Ostdam17, Virginia Pascual-Ramos18, Javier Merayo-Chalico18, Istar Guzmán-Sánchez19, María Esther Pérez-Bastidas20, Jorge Enrique Aguilar Arreola21, Alejandra López Rodríguez22, Greta Reyes-Cordero23, Humberto Alfredo Ricardez24, María Fernanda Hernández Cabrera25, Guadalupe Olvera-Soto26, Daniel Xibillé Friedmann27. 1. Centro de Investigación Clínica de Morelia, Morelia, Mich, México. 2. Hospital regional 1ro de Octubre, Ciudad de México, México. 3. Coordinación de Investigación, Instituto Mexicano del Seguro Social (IMSS), Ciudad de México, México. 4. Servicio de Reumatología, CMN 20 de Noviembre, ISSSTE, Ciudad de México, México. 5. Facultad de Medicina, Universidad Autónoma de Chihuahua, Chihuahua, México. 6. Departamento de Reumatología, Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de México, México. 7. Jefatura de Enseñanza e Investigación Hospital Central Norte PEMEX, Ciudad de México, México. 8. Servicio de Reumatología, Hospital Civil de Guadalajara Fray Antonio Alcalde, Guadalajara, Jalisco, México. 9. Servicio de Reumatología, Hospital Civil de Guadalajara Fray Antonio Alcalde, Guadalajara, Jalisco, México; Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, México. 10. Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, México; Clínica de Investigación en Reumatología y Obesidad, Guadalajara, Jalisco, México. 11. Hospital de Especialidades No 71, Unidad Médica de Alta Especialidad (UMAE), Torreón, Coahuila, México. 12. Hospital Ángeles del Pedregal, Ciudad de México, México. 13. Unidad Médica de Alta Especialidad No. 25, Hospital de Especialidades IMSS, Monterrey, Nuevo León, México. 14. Hospital de Especialidades CMN Siglo XXI, IMSS, Ciudad de México, México. 15. Colegio Mexicano de Reumatología AC, Ciudad de México, México. 16. Hospital Ángeles, Hospital Regional ISSSTE, Puebla, Puebla, México. 17. Unidad de Investigaciones Reumatológicas, Hospital Central Dr. Ignacio Morones Prieto, Facultad de Medicina, Universidad Autónoma de San Luis Potosí, San Luis Potosí, S.L.P., México. 18. Departamento de Inmunología y Reumatología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, México. 19. Centro Médico Instituto de Seguridad Social del Estado de México y Municipios, Toluca, Estado de México, México. 20. Colegio Jalisciense de Reumatología, Guadalajara, Jalisco, México. 21. Hospital Civil de Guadalajara Dr. Juan I. Menchaca, Guadalajara, Jalisco, México. 22. Dermatológico Country, Centro de Investigación de Enfermedades Autoinmunes, Guadalajara, Jalisco, México. 23. Hospital Ángeles Chihuahua, Chihuahua, México. 24. Centro de Especialidades Médicas del Instituto de Seguridad Social del Estado de Tabasco. Universidad Juárez Autónoma de Tabasco, División Académica de Ciencias de la Salud, Villahermosa, Tabasco, México. 25. Hospital General Regional 220 IMSS, Toluca, Estado de México, México. 26. Comisión Nacional de Protección Social en Salud, Ciudad de México, México. 27. Departamento de Investigación y Capacitación, Servicios de Salud de Morelos, Cuernavaca, Morelos, México. Electronic address: daniel.xibille@uaem.mx.
Abstract
Therapeutic advances in rheumatoid arthritis require periodic review of treatment guidelines. OBJECTIVE: To update the Mexican College of Rheumatology guidelines on the pharmacological treatment of rheumatoid arthritis. METHOD: Board certified rheumatologists from different health institutions and regions of the country participated. Work teams were formed that reviewed the previous guidelines, elaborated new questions, reviewed the literature, and scored the evidence that was presented and discussed in plenary session. The conclusions were presented to infectologists, gynaecologists and patients. Recommendations were based on levels of evidence according to GRADE methodology. RESULTS: Updated recommendations on the use of available medications for rheumatoid arthritis treatment in Mexico up to 2017 are presented. The importance of adequate and sustained control of the disease is emphasized and relevant safety aspects are described. Bioethical conflicts are included, and government action is invited to strengthen correct treatment of the disease. CONCLUSIONS: The updated recommendations of the Mexican College of Rheumatology on the pharmacological treatment of rheumatoid arthritis incorporate the best available information to be used in the Mexican health care system.
Therapeutic advances in rheumatoid arthritis require periodic review of treatment guidelines. OBJECTIVE: To update the Mexican College of Rheumatology guidelines on the pharmacological treatment of rheumatoid arthritis. METHOD: Board certified rheumatologists from different health institutions and regions of the country participated. Work teams were formed that reviewed the previous guidelines, elaborated new questions, reviewed the literature, and scored the evidence that was presented and discussed in plenary session. The conclusions were presented to infectologists, gynaecologists and patients. Recommendations were based on levels of evidence according to GRADE methodology. RESULTS: Updated recommendations on the use of available medications for rheumatoid arthritis treatment in Mexico up to 2017 are presented. The importance of adequate and sustained control of the disease is emphasized and relevant safety aspects are described. Bioethical conflicts are included, and government action is invited to strengthen correct treatment of the disease. CONCLUSIONS: The updated recommendations of the Mexican College of Rheumatology on the pharmacological treatment of rheumatoid arthritis incorporate the best available information to be used in the Mexican health care system.
Authors: Susana Aideé González-Chávez; César Pacheco-Tena; Teresita de Jesús Caraveo-Frescas; Celia María Quiñonez-Flores; Greta Reyes-Cordero; Rosa María Campos-Torres Journal: Rheumatol Int Date: 2019-09-17 Impact factor: 2.631
Authors: Gabriel Figueroa-Parra; Andrea Moreno-Salinas; Leticia Santoyo-Fexas; Carmen Magdalena Gamboa-Alonso; Juan Pablo Carrizales-Luna; Ivan de Jesus Hernandez-Galarza; Dionicio Angel Galarza-Delgado; Jorge Antonio Esquivel-Valerio Journal: Reumatologia Date: 2022-01-12
Authors: Gabriel Figueroa-Parra; Jorge Antonio Esquivel-Valerio; Leticia Santoyo-Fexas; Andrea Moreno-Salinas; Carmen Magdalena Gamboa-Alonso; Ana Laura De Leon-Ibarra; Dionicio Angel Galarza-Delgado Journal: Hum Vaccin Immunother Date: 2020-09-29 Impact factor: 3.452